Coherus BioSciences (CHRS) Misses Q2 EPS by 60c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. QGEN

Go back to Coherus BioSciences (CHRS) Misses Q2 EPS by 60c

Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results

March 13, 2017 4:01 PM EDT

REDWOOD CITY, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the fourth quarter and full year 2016.

Corporate Highlights for the Fourth Quarter 2016 Include:Oncology therapeutic franchise:

CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate)- Announced that the U.S. FDA has accepted the filing of 351(k) Biologics License Application (BLA) for CHS-1701. The first FDA submission and acceptance for Coherus.- Announced acceptance of Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CHS-1701. This is the... More